HHS CISO Chris Wlaschin to be replaced by deputy CIO from CMS

Chris Wlaschin, who has served as chief information security officer (CISO) at HHS since January 2017, will leave the post at the end of March amid allegations cybersecurity vendors had given gifts and privileges to lower-level government IT leaders involved with the Healthcare Cybersecurity Communications and Integration Center (HCCIC).

Nextgov confirmed Wlaschin will step down, but he said his departure was entirely for “personal and family reasons” unrelated to the HCCIC controversy.

Taking over the CISO role will be Janet Vogel, deputy chief information officer at CMS. Vogel previously led the Financial Management System Group within CMS and worked in tech departments of both the Department of Transportation and the U.S. Agency for International Development.

“Janet brings 30 years of federal experience to the position with the last 16 years at CMS,” a CMS spokesperson said to Nextgov. “Her broad spectrum of skills in information technology, information security, organizational change, acquisition and risk mitigation will be key to transforming and expanding HHS’ cyber programs into the healthcare sector.”

Read the full story below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.